我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

不对称二甲基精氨酸在心血管疾病中的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第1期
页码:
127-130
栏目:
综述
出版日期:
2009-02-28

文章信息/Info

Title:
-
作者:
陈骁 综述; 张怀勤 审校
温州医学院附属第一医院心内科，浙江 温州 325000
Author(s):
-
关键词:
不对称二甲基精氨酸; 心血管疾病; 药物治疗; 危险因子
Keywords:
-
分类号:
R54；R453
DOI:
-
文献标识码:
A
摘要:
不对称二甲基精氨酸不论是作为心血管疾病的一个药物治疗靶点还是作为一个危险因子，都有广阔的临床意义和应用前景，将为心血管疾病的治疗提供新的思路和理论基础。本文就不对称二甲基精氨酸在心血管疾病中的作用及研究进展的作一番综述。
Abstract:
-

参考文献/References

[1］ Kielstein A, Tsikas D, Galloway GP, et al. Asymmetric dimethylarginine(ADMA)-a modulator of nociception in opiate tolerance and addiction? ［J］. Nitric Oxide, 2007, 17(2):55-59.
［2］ Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis［J］. Nat Med, 2007, 13(2):198-203.
［3］ Wang J, Sim AS, Wang XL, et al. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells［J］. Cell Mol Life Sci, 2006, 63(23):2838-2846.
［4］ 梁红霞，路雪芹. 充血性心力衰竭患者内皮功能的变化［J］. 第四军医大学学报, 2004, 25(7)：647.
［5］ 马建林，王圣，李新明，等. 冠心病患者内皮功能与血清SOD、丙二醛含量相关［J］. 心脏杂志, 2006， 18(3):320-322.
［6］ Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibi-tor asymmetric dimethylarginine［J］. J Am Coll Cardiol, 2005, 46(9):1693-1701.
［7］ Jacobi J, Sydow K, Von Pegenfeld G, et al. Overexpression of dimethylarginine dimethylam-inohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis［J］. Circulation, 2005, 111(11):1431-1438.
［8］ Furuki K, Adachi H, Matsuoka H, et al. Plasma levels of dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study［J］. Atherosclerosis, 2007, 191(1):206-210.
［9］Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans［J］. Stroke, 2006, 37(8):2024-2029.
［10］Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans［J］. Circulation, 2004, 109(2):172-177.
［11］Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunc-tion in CKD: oxidative stress and asymmetric dimethylarginine［J］. Am J Kidney Dis, 2006, 47(1):42-50.
［12］Kielstein JT, Bode-Boger SM, Hesse G, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension［J］. Arterioscler Thromb Vasc Biol, 2005, 25(7):1414-1418.
［13］Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study)［J］. Clin Chem,2007, 53(2):273-283.
［14］Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study［J］. Circ Res, 2005, 97(5):e53-e59.
［15］Krempl TK, Maas R, Sydow K, et al. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events［J］. Eur Heart J, 2005, 26(18):1846-1851.
［16］Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study［J］. Am Heart J, 2006, 152(3):493.e1-493.08.
［17］Korandji C, Zeller M, Guilland JC, et al. Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction［J］. Clin Biochem, 2007, 40(1-2):66-72.
［18］Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced periphe-ral artery disease［J］. Arterioscler Thromb Vasc Biol, 2006, 26(11):2536-2540.
［19］ Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension［J］. J Am Coll Cardiol, 2005, 46(3):518-5123.
［20］Ardigo D, St ehlinger M, Franzini L, et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk［J］. Eur J Clin Invest, 2007, 37(4):263-269.
［21］Bode-Bger SM, Scalera F, Martens-Lobenhoffer J. Asymmetric dimethylarginine (ADMA) accelerates cell senescence［J］. Vasc Med, 2005, 10（Suppl 1）:S65-S71.
［22］Richter B, Niessner A, Penka M, et al. Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events［J］. Thromb Haemost, 2005, 94(6):1306-1311.

备注/Memo

备注/Memo:
收稿日期：2007-8-13.通讯作者:张怀勤，主任医师，主要从事心血管疾病临床基础 研究Email:lhuaiqinzhang@163.com 作者简介:陈骁，硕士生Email:chenxiao0909@163.com
更新日期/Last Update: 2009-04-02